Warfarin

The CLH proposals for the eight anticoagulants have been submitted by eight different Member State competent authorities and concern the following substances: chlorophacinone, difenacoum, warfarin, difethialone, bromadiolone, coumatetralyl, brodifacoum and flocoumafen. These anticoagulants are all r more

Teaneck, NJ and Titusville, NJ (February 15, 2002) -- Eisai Inc. and Janssen Pharmaceutica Inc. announced today that the U.S. Food and Drug Administration has approved the expanded use of the PPI, ACIPHEX® (rabeprazole sodium), to include the treatment of daytime and nighttime heartburn and other sy more

Molecules, Vol. 23, Pages 1452: Anticoagulant Activities of Indobufen, an Antiplatelet Drug Molecules doi: 10.3390/molecules23061452 Authors: Jia Liu Dan Xu Nian Xia Kai Hou Shijie Chen Yu Wang Yunman Li Indobufen is a new generation of anti-platelet aggregation drug, but more

Publication date: September 2018 Source:Microchemical Journal, Volume 141 Author(s): Faten Farouk, Samir Nabhan, Wilfried M.A. Niessen, Hassan M.E. Azzazy Warfarin (WRN) use is plagued by response fluctuation which is managed by dose adjustment. The plasma WRN level had always been an more

Mass spectrometry-based footprinting is an emerging approach for studying protein structure. Because integral membrane proteins are difficult targets for conventional structural biology, we recently developed a mass spectrometry (MS) footprinting method to probe membrane protein–drug interactions in more